Genelux Corporation (GNLX)
Genelux Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Genelux Corporation (GNLX) is a Biotechnology company based in US with a market capitalization of $129.6M. Revenue grew 0.0% year-over-year and free cash flow was negative at -$26.4M. This page tracks GNLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 24 employees · IPO Jan 26, 2023
Valuation
Valuation & price
$2.92as of May 17, 2026· -64.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
11.23
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$129.6M
Market cap
0.0%
Revenue growth (YoY)
-7075.0%
Gross margin
-$26.4M
Free cash flow (USD)
-$12.9M
Net debt
Net cash position
18.2%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
6
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 22, 2026Filing
Annual Meeting Results
- Insider sellJun 4, 2026Filing
Insider Sell $563Smalling Ralph · Head of Regulatory · $562.6
- Insider sellJun 2, 2026Filing
Insider Sell $30K · 10b5-1 PlanThomas John · Director · $29.8K
- Insider sellMay 12, 2026Filing
Insider Sell $804Smalling Ralph · Head of Regulatory · $804.5
- Insider sellMay 12, 2026Filing
Insider Sell $8KZindrick Thomas · President and CEO · $8.2K
- Insider sellMay 12, 2026Filing
Insider Sell $2KCappello Joseph · Chief Technical Officer · $1.8K
- Insider sellMay 12, 2026Filing
Insider Sell $2KYu Yong · Chief Scientific Officer · $1.8K
- Quarterly reportMay 7, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Genelux Corporation's market cap?
Genelux Corporation (GNLX) has a market capitalization of $129.6M.
What is GNLX's P/E ratio?
A meaningful P/E ratio is not available for GNLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is GNLX's price-to-book (P/B) ratio?
GNLX trades at 11.23 times book value per share.
Are insiders buying GNLX stock?
SEC Form 4 filings show no open-market insider buys at Genelux Corporation in the last 90 days (6 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.